Oruka Therapeutics (ORKA) Non-Current Assets (2010 - 2026)
Oruka Therapeutics (ORKA) posted quarterly Non-Current Assets of $109.2 million for Q1 2026, up 336.42% year-over-year from $25.0 million in Q1 2025, and down 24.54% quarter-over-quarter from $144.8 million in Q4 2025.
Oruka Therapeutics (ORKA) Non-Current Assets (2010 - 2026) Analysis & Trends
Oruka Therapeutics' Non-Current Assets history runs 17 years deep, the most recent figure standing at $109.2 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 336.42% year-over-year to $109.2 million; the TTM figure through Mar 2026 stood at $433.5 million (up 855.99% YoY), while the FY2025 annual figure was $144.8 million, up 655.93% from the prior year.
- Non-Current Assets for Q1 2026 stood at $109.2 million, down from $144.8 million in the prior quarter.
- The five-year high for Non-Current Assets was $154.1 million in Q3 2025, with the low at $24000.0 in Q2 2024.
- The 5-year median for Non-Current Assets is $446000.0 (2022), against an average of $28.3 million.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets tumbled 92.68% in 2024, then surged 105758.33% in 2025.
- Oruka Therapeutics' Non-Current Assets stood at $386000.0 in 2022, then plunged by 30.31% to $269000.0 in 2023, then soared by 7018.96% to $19.2 million in 2024, then soared by 655.93% to $144.8 million in 2025, then dropped by 24.54% to $109.2 million in 2026.
- Business Quant data shows ORKA's Non-Current Assets at $109.2 million in Q1 2026, $144.8 million in Q4 2025, and $154.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Oruka Therapeutics | 6.98 Bn | 5.25 Bn | - | 254.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 254.84 Mn |
| Mar 31, 2026 | 109.23 Mn |
| Dec 31, 2025 | 144.76 Mn |
| Sep 30, 2025 | 154.09 Mn |
| Jun 30, 2025 | 25.41 Mn |
| Mar 31, 2025 | 25.03 Mn |
| Dec 31, 2024 | 19.15 Mn |
| Sep 30, 2024 | 1.14 Mn |
| Jun 30, 2024 | 24,000.00 |
| Mar 31, 2024 | 36,000.00 |
| Dec 31, 2023 | 269,000.00 |
| Sep 30, 2023 | 292,000.00 |
| Jun 30, 2023 | 328,000.00 |
| Mar 31, 2023 | 357,000.00 |
| Dec 31, 2022 | 386,000.00 |
| Sep 30, 2022 | 415,000.00 |
| Jun 30, 2022 | 446,000.00 |
| Mar 31, 2022 | 475,000.00 |
| Dec 31, 2021 | 503,000.00 |
| Sep 30, 2021 | 526,000.00 |